These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 16836499

  • 1. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
    Pedraz J, Daudén E, Delgado-Jiménez Y, García-Río I, García-Díez A.
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
    Akhyani M, Chams-Davatchi C, Hemami MR, Fateh S.
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
    [Abstract] [Full Text] [Related]

  • 3. A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis.
    Beissert S, Pauser S, Sticherling M, Frieling U, Loske KD, Frosch PJ, Haase I, Luger TA.
    Dermatology; 2009 Dec; 219(2):126-32. PubMed ID: 19546522
    [Abstract] [Full Text] [Related]

  • 4. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis.
    Daudén E, Sánchez-Peinado C, Ruiz-Genao D, García-F-Villalta M, Onate MJ, García-Díez A.
    Br J Dermatol; 2004 Jan; 150(1):132-5. PubMed ID: 14746627
    [Abstract] [Full Text] [Related]

  • 5. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis.
    Davison SC, Morris-Jones R, Powles AV, Fry L.
    Br J Dermatol; 2000 Aug; 143(2):405-7. PubMed ID: 10951153
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients.
    Geilen CC, Arnold M, Orfanos CE.
    Br J Dermatol; 2001 Mar; 144(3):583-6. PubMed ID: 11260019
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
    Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE, Sirolimus European Psoriasis Study Group.
    Br J Dermatol; 2001 Sep; 145(3):438-45. PubMed ID: 11531834
    [Abstract] [Full Text] [Related]

  • 8. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis.
    Ameen M, Smith HR, Barker JN.
    Clin Exp Dermatol; 2001 Sep; 26(6):480-3. PubMed ID: 11678869
    [Abstract] [Full Text] [Related]

  • 9. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients.
    Zimmerman AB, Berger EM, Elmariah SB, Soter NA.
    J Am Acad Dermatol; 2012 May; 66(5):767-70. PubMed ID: 21783274
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R, Sánchez Regaña M, Massana J, Oliete R, Umbert P.
    J Dermatolog Treat; 2005 May; 16(4):238-41. PubMed ID: 16249146
    [Abstract] [Full Text] [Related]

  • 11. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
    Salek MS, Finlay AY, Lewis JJ, Sumner MI.
    Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic drug monitoring of mycophenolic acid in patients with psoriasis.
    Daudén E, Pedraz J, Alvarez-Ruiz S, García-Río I, Sánchez-Peinado C, Oñate MJ, García-Diez A.
    Eur J Dermatol; 2010 Feb; 20(3):321-2. PubMed ID: 20146966
    [Abstract] [Full Text] [Related]

  • 13. Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial.
    Zhou Y, Rosenthal D, Dutz J, Ho V.
    J Cutan Med Surg; 2003 Feb; 7(3):193-7. PubMed ID: 12704533
    [Abstract] [Full Text] [Related]

  • 14. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
    Vena GA, Galluccio A, Pezza M, Vestita M, Cassano N.
    J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
    [Abstract] [Full Text] [Related]

  • 15. Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study.
    Fallah Arani S, Waalboer Spuij R, Nijsten T, Neumann HA, Thio B.
    J Dermatolog Treat; 2014 Feb; 25(1):46-9. PubMed ID: 22998609
    [Abstract] [Full Text] [Related]

  • 16. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
    Peluso AM, Bardazzi F, Tosti A, Varotti C.
    Acta Derm Venereol Suppl (Stockh); 1994 Feb; 186():90-1. PubMed ID: 8073851
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB.
    Am J Clin Dermatol; 2010 Feb; 11(4):275-83. PubMed ID: 20513160
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
    Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, Reitamo S, Ohannesson A, Mørk NJ, Clarke P, Pfister P, Paul C.
    Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety of mycophenolate mofetil and cyclosporine: a review.
    Buell C, Koo J.
    J Drugs Dermatol; 2008 Aug; 7(8):741-8. PubMed ID: 18720690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.